Influence of Apolipoprotein A-I Domain Structure on Macrophage Reverse Cholesterol Transport in Mice
Overview
Authors
Affiliations
Objective: The goal of this study was to determine the influence of apolipoprotein A-I (apoA-I) tertiary structure domain properties on the antiatherogenic properties of the protein. Two chimeric hybrids with the N-terminal domains swapped (human-mouse apoA-I and mouse-human apoA-I) were expressed in apoA-I-null mice with adeno-associated virus (AAV) and used to study macrophage reverse cholesterol transport (RCT) in vivo.
Methods And Results: The different apoA-I variants were expressed in apoA-I-null mice that were injected with [H(3)]cholesterol-labeled J774 mouse macrophages to measure RCT. Significantly more cholesterol was removed from the macrophages and deposited in the feces via the RCT pathway in mice expressing mouse-H apoA-I compared with all other groups. Analysis of the individual components of the RCT pathway demonstrated that mouse-H apoA-I promoted ATP-binding cassette transporter A1-mediated cholesterol efflux more efficiently than all other variants, as well as increasing the rate of cholesterol uptake into liver cells.
Conclusions: The structural domain properties of apoA-I affect the ability of the protein to mediate macrophage RCT. Replacement of the N-terminal helix bundle domain in the human apoA-I with the mouse apoA-I counterpart causes a gain of function with respect to macrophage RCT, suggesting that engineering some destabilization into the N-terminal helix bundle domain or increasing the hydrophobicity of the C-terminal domain of human apoA-I would enhance the antiatherogenic properties of the protein.
Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics.
Maslyanko M, Harris R, Mu D Int J Mol Sci. 2021; 22(13).
PMID: 34281263 PMC: 8268178. DOI: 10.3390/ijms22137209.
The Susceptibility to Diet-Induced Atherosclerosis Is Exacerbated with Aging in C57B1/6 Mice.
Simo O, Berrougui H, Fulop T, Khalil A Biomedicines. 2021; 9(5).
PMID: 33946646 PMC: 8146644. DOI: 10.3390/biomedicines9050487.
Lek M, Cruz S, Ibe N, Beck W, Bielicki J, Weers P PLoS One. 2017; 12(6):e0178346.
PMID: 28644829 PMC: 5482431. DOI: 10.1371/journal.pone.0178346.
Horn J, Ellena R, Tran J, Beck W, Narayanaswami V, Weers P Biochim Biophys Acta Biomembr. 2017; 1859(8):1317-1325.
PMID: 28434970 PMC: 5518692. DOI: 10.1016/j.bbamem.2017.04.017.
Wang Q, Li C, Zhang Q, Wang Y, Shi T, Lu L BMC Complement Altern Med. 2016; 16(1):514.
PMID: 27955667 PMC: 5153825. DOI: 10.1186/s12906-016-1496-z.